Stock Scorecard
Stock Summary for Heron Therapeutics Inc (HRTX) - $2.35 as of 3/28/2025 8:05:52 PM EST
Total Score
8 out of 30
Safety Score
26 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for HRTX
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for HRTX
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for HRTX
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for HRTX
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for HRTX (26 out of 100)
Stock Price Rating (Max of 10) | 3 |
Historical Stock Price Rating (Max of 10) | 4 |
Stock Price Trend (Max of 10) | 1 |
Book Value (Max of 10) | 1 |
Book Value to Price (Max of 10) | 0 |
Analyst Buy Ratings (Max of 5) | 3 |
Analyst Strong Buy Ratings (Max of 5) | 3 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 3 |
Trading Volume (Max of 10) | 8 |
Price to Earnings (Max of 10) | 0 |
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for HRTX
Financial Details for HRTX
Company Overview |
|
---|---|
Ticker | HRTX |
Company Name | Heron Therapeutics Inc |
Country | USA |
Description | Heron Therapeutics, Inc., a biotechnology company, is dedicated to developing treatments to address unmet medical needs. The company is headquartered in San Diego, California. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 12/31/2024 |
Next Earnings Date | 5/5/2025 |
Stock Price History |
|
Last Day Price | 2.35 |
Price 4 Years Ago | 9.13 |
Last Day Price Updated | 3/28/2025 8:05:52 PM EST |
Last Day Volume | 752,085 |
Average Daily Volume | 2,201,582 |
52-Week High | 3.93 |
52-Week Low | 1.04 |
Last Price to 52 Week Low | 125.96% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 37.01 |
Sector PE | 40.10 |
5-Year Average PE | -6.53 |
Free Cash Flow Ratio | 5.00 |
Industry Free Cash Flow Ratio | 11.91 |
Sector Free Cash Flow Ratio | 47.05 |
Current Ratio Most Recent Quarter | 2.28 |
Total Cash Per Share | 0.47 |
Book Value Per Share Most Recent Quarter | -0.22 |
Price to Book Ratio | 12.60 |
Industry Price to Book Ratio | 8.86 |
Sector Price to Book Ratio | 21.92 |
Price to Sales Ratio Twelve Trailing Months | 2.48 |
Industry Price to Sales Ratio Twelve Trailing Months | 88.85 |
Sector Price to Sales Ratio Twelve Trailing Months | 27.78 |
Analyst Buy Ratings | 2 |
Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
Total Shares Outstanding | 152,330,000 |
Market Capitalization | 357,975,500 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Previous Dividend Amount | 0.0000 |
Current Dividend Amount | 0.0000 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.55% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 39.26% |
Reported EPS 12 Trailing Months | -0.09 |
Reported EPS Past Year | -0.09 |
Reported EPS Prior Year | -0.86 |
Net Income Twelve Trailing Months | -27,967,000 |
Net Income Past Year | -110,559,000 |
Net Income Prior Year | -182,024,000 |
Quarterly Revenue Growth YOY | 19.10% |
5-Year Revenue Growth | 10.47% |
Operating Margin Twelve Trailing Months | 10.20% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 70,900,000 |
Total Cash Past Year | 80,400,000 |
Total Cash Prior Year | 84,900,000 |
Net Cash Position Most Recent Quarter | -78,747,000 |
Net Cash Position Past Year | -69,090,000 |
Long Term Debt Past Year | 149,490,000 |
Long Term Debt Prior Year | 149,284,000 |
Total Debt Most Recent Quarter | 149,647,000 |
Equity to Debt Ratio Past Year | -0.29 |
Equity to Debt Ratio Most Recent Quarter | -0.36 |
Total Stockholder Equity Past Year | -33,973,000 |
Total Stockholder Equity Prior Year | 13,572,000 |
Total Stockholder Equity Most Recent Quarter | -40,005,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -9,612,000 |
Free Cash Flow Per Share Twelve Trailing Months | -0.06 |
Free Cash Flow Past Year | -60,334,000 |
Free Cash Flow Prior Year | -148,737,000 |
Options |
|
Put/Call Ratio | 0.18 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.11 |
MACD Signal | 0.14 |
20-Day Bollinger Lower Band | 0.97 |
20-Day Bollinger Middle Band | 1.76 |
20-Day Bollinger Upper Band | 2.56 |
Beta | 1.55 |
RSI | 55.38 |
50-Day SMA | 2.24 |
150-Day SMA | 2.36 |
200-Day SMA | 4.24 |
System |
|
Modified | 3/27/2025 10:31:06 PM EST |